Toronto Dominion Bank cut its position in Humana Inc (NYSE:HUM) by 99.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 226 shares of the insurance provider’s stock after selling 99,900 shares during the quarter. Toronto Dominion Bank’s holdings in Humana were worth $34,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of HUM. High Pointe Capital Management LLC acquired a new position in Humana during the second quarter valued at approximately $744,000. State Board of Administration of Florida Retirement System grew its holdings in Humana by 1.6% during the second quarter. State Board of Administration of Florida Retirement System now owns 187,119 shares of the insurance provider’s stock valued at $72,555,000 after purchasing an additional 3,010 shares during the period. Rafferty Asset Management LLC grew its holdings in Humana by 225.0% during the second quarter. Rafferty Asset Management LLC now owns 3,322 shares of the insurance provider’s stock valued at $1,288,000 after purchasing an additional 2,300 shares during the period. Sentry Investment Management LLC acquired a new position in Humana during the second quarter valued at approximately $2,932,000. Finally, Victory Capital Management Inc. grew its holdings in Humana by 7.3% during the second quarter. Victory Capital Management Inc. now owns 210,750 shares of the insurance provider’s stock valued at $81,718,000 after purchasing an additional 14,335 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.
NYSE HUM traded down $2.93 on Thursday, hitting $415.07. 10,212 shares of the stock were exchanged, compared to its average volume of 574,770. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.69 and a quick ratio of 1.69. The business’s fifty day moving average is $399.58 and its 200 day moving average is $366.29. Humana Inc has a 52 week low of $208.25 and a 52 week high of $425.46. The company has a market capitalization of $55.19 billion, a PE ratio of 15.79, a P/E/G ratio of 1.81 and a beta of 0.86.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 5th. The insurance provider reported $12.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $10.34 by $2.22. Humana had a net margin of 4.96% and a return on equity of 26.70%. The firm had revenue of $19.08 billion for the quarter, compared to analyst estimates of $18.66 billion. During the same period in the prior year, the firm posted $6.05 earnings per share. The company’s quarterly revenue was up 17.5% compared to the same quarter last year. Analysts predict that Humana Inc will post 18.7 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.625 per share. This represents a $2.50 annualized dividend and a yield of 0.60%. Humana’s dividend payout ratio (DPR) is currently 13.99%.
A number of research analysts have weighed in on HUM shares. CSFB lifted their price target on shares of Humana from $400.00 to $423.00 and gave the company an “outperform” rating in a research note on Thursday, April 30th. Cowen reaffirmed a “market perform” rating and issued a $410.00 price target on shares of Humana in a research note on Tuesday, June 16th. They noted that the move was a valuation call. Piper Sandler lifted their price target on shares of Humana from $442.00 to $473.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Citigroup lifted their price target on shares of Humana from $424.00 to $435.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Royal Bank of Canada lifted their price target on shares of Humana from $388.00 to $420.00 and gave the company a “sector perform” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average target price of $425.50.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: Tariff
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.